Samba TV Announces Acquisition of Semasio, Strengthening its Position in Contextual Targeting 31-10-2024, 19:30

CRMNEXT expands to BUSINESSNEXT 2-03-2023, 10:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00